Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Nov;33(11):2490-6.
doi: 10.1007/s00268-009-0189-x.

The outcome of the axillofemoral bypass: a retrospective analysis of 45 patients

Marjolein H Liedenbaum  1 , Froukje J Verdam, David Spelt, Hans G W de Groot, Jan van der Waal, Lijckle van der Laan
Affiliations

The outcome of the axillofemoral bypass: a retrospective analysis of 45 patients

Marjolein H Liedenbaum et al. World J Surg. 2009 Nov.

Abstract

Purpose: This study was designed to retrospectively analyze outcomes of axillofemoral bypass (AxFB) operations performed in patients with severe comorbidities.

Methods: All patients (n = 45) who received an AxFB between 1990 and 2005 for aortoiliac occlusive disease (AIOD, n = 35) or infectious aortic disease (IAD, n = 10) were included. Information on patency of the bypass and mortality was retrieved from patient records. A Kaplan-Meier survival analysis was performed to illustrate survival rates, limb salvage, and primary and secondary patency.

Results: Included patients had several comorbidities and a high operative risk. In this group, a 30-day mortality rate of 20% was found: 17% for the AIOD group, and 30% for the IAD group. During 5-year follow-up 20 patients died, of which 15 during the first year after operation. Survival rates were at 64 and 41% at 1 and 5 years and limb salvage rates were 84% for both these years. Primary patency rates at 1 and 5 years were 72 and 58%, respectively, and secondary patency rates were 86% at both time points.

Conclusions: High mortality rates were found in AIOD or IAD patients who received an AxFB. However, for high-risk patients with an already reduced life expectancy, the AxFB remains an alternative with acceptable patency rates.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
In the left figure survival until 5 years is shown for the total group and in the right figure for the infectious aortic disease group (—) and the aortoiliac occlusive disease group (–). The censored points (● and +) are the patients who were lost during follow-up
Fig. 2
Fig. 2
In the left figure primary patency until 5 years is shown for the total group and in the right figure for the infectious aortic disease group (—) and the aortoiliac occlusive disease group (–). The censored points (● and +) are the patients who were lost during follow-up
Fig. 3
Fig. 3
In the left figure secondary patency until 5 years is shown for the total group and in the right figure for the infectious aortic disease group (—) and the aortoiliac occlusive disease group (–). The censored points (● and +) are the patients who were lost during follow-up
See this image and copyright information in PMC

References

    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1067/mva.2000.109471', 'is_inner': False, 'url': 'https://doi.org/10.1067/mva.2000.109471'}, {'type': 'PubMed', 'value': '10957651', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/10957651/'}]}
    2. Seeger JM, Pretus HA, Welborn MB et al (2000) Long-term outcome after treatment of aortic graft infection with staged extra-anatomic bypass grafting and aortic graft removal. J Vasc Surg 32:451–459 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/S0741-5214(99)70178-3', 'is_inner': False, 'url': 'https://doi.org/10.1016/s0741-5214(99)70178-3'}, {'type': 'PubMed', 'value': '10394156', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/10394156/'}]}
    2. Yeager RA, Taylor LM Jr, Moneta GL et al (1999) Improved results with conventional management of infrarenal aortic infection. J Vasc Surg 30:76–83 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '10661822', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/10661822/'}]}
    2. Jamsen T, Tulla H, Loponen P (1999) Axillofemoral bypass operations in Kuopio University Hospital 1985–1996. Ann Chir Gynaecol 88:269–275 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/S0741-5214(96)70270-7', 'is_inner': False, 'url': 'https://doi.org/10.1016/s0741-5214(96)70270-7'}, {'type': 'PubMed', 'value': '8637103', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/8637103/'}]}
    2. Passman MA, Taylor LM, Moneta GL, Edwards JM, Yeager RA, McConnell DB, Porter JM (1996) Comparison of axillofemoral and aortofemoral bypass for aortoiliac occlusive disease. J Vasc Surg 23:263–271 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/S0002-9610(00)00426-8', 'is_inner': False, 'url': 'https://doi.org/10.1016/s0002-9610(00)00426-8'}, {'type': 'PubMed', 'value': '11044521', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/11044521/'}]}
    2. Martin D, Katz SG (2000) Axillofemoral bypass for aortoiliac occlusive disease. Am J Surg 180:100–103 - PubMed

LinkOut - more resources